Objective Regulatory T cells (Tregs) prevent autoimmunity and control inflammation.
Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose …

Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector
T cells (Teffs) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression …

In addition to CD4 + regulatory T cells (Tregs), CD8 + suppressor T cells are emerging as
an important subset of regulatory T cells. Diverse populations of CD8 + T cells with …

Aims/hypothesis Low-dose IL-2 (ld-IL2) selectively activates and expands regulatory T cells (Tregs)
and thus has the potential to skew the regulatory/effector T (Treg/Teff) cell balance …

Introduction Autoimmune and autoinflammatory diseases (AIDs) represent a socioeconomic
burden as the second cause of chronic illness in Western countries. In this context, the …

Background A Tregs insufficiency is central to autoimmune and inflammatory diseases
pathophysiology and low dose interleukin-2 (IL-2 LD ) can specifically activate Tregs. Objective …

We used these in vivo data to model the dose/scheme effects of IL-2 on Treg cells in mice
during induction and maintenance phases. Data of Treg-cell expansion versus time were …

Background Systemic sclerosis (SSc) is a chronic autoimmune disease, with impaired
immune response, increased fibrosis and endothelial dysfunction. Regulatory T cells (Tregs), …

Objectives Based on genetic associations, McGonagle and McDermott suggested a
classification of autoimmune and autoinflammatory diseases as a continuum ranging from purely …

Commenting on Meyer et al 1 our recent publication 2 ‘Immunological and clinical effects of
low-dose interleukin-2 (IL-2) across 11 autoimmune diseases in a single, open clinical trial’, …